Quris-AI Acquires Nortis
October 29, 2024 07:00 ET
|
Quris Technologies
BOSTON and TEL AVIV, Israel, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Quris-AI (Quris), a leading Bio-AI company focused on revolutionizing the pharmaceutical drug development process, today announced the...
Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration
September 28, 2023 08:00 ET
|
Quris Technologies
Merck KGaA and Quris-AI Expand Collaboration After a Successful Preclinical Study Assessed the Quris-AI BioAI Drug Safety Platform
Global Oxycodone Hydrochloride Market Size Scaling New Heights With $578.94 Million Projection by 2030, Showing a 4.66% CAGR
August 19, 2023 19:00 ET
|
Zion Market Research
New York, NY, Aug. 19, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Oxycodone Hydrochloride Market By Type (Controlled-Release And Immediate-Release), By...
Quris-AI Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
March 02, 2023 07:00 ET
|
Quris Technologies
BOSTON and TEL-AVIV, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- Quris-AI, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023. This year’s...
Quris Earns Additional Seed Investment Led by SoftBank Vision Fund 2
December 20, 2022 08:00 ET
|
Quris Technologies
BOSTON and TEL-AVIV, Israel, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has secured an additional $9...
Deepfake Technology in Drug Design
October 20, 2022 12:00 ET
|
InSilico Medicine
New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage artificial intelligence (AI)-driven drug discovery company, is utilizing the same deepfake technology used to create...
Walden Biosciences Appoints Peter Guest Linde, M.D. as Chief Medical Officer
October 11, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Research Collaboration with University of Michigan
July 05, 2022 09:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction
February 10, 2022 00:00 ET
|
Quris Technologies
BOSTON and TEL-AVIV, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed an agreement with...
Pace® Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services
October 11, 2021 07:45 ET
|
Pace Analytical
MINNEAPOLIS, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development and manufacturing organization...